NEW YORK - September 3, 2025 (NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks ...
On July 22, 2025, Replimune publicly announced that the U.S. Food and Drug Administration (FDA) had issued a "Complete Response Letter" (CRL) for its Biologics License Application (BLA) for RP1. This ...
MSN ನಲ್ಲಿ ಹೋಸ್ಟ್ ಮಾಡಲಾಗಿದೆ
JP Morgan Downgrades Replimune Group (REPL)
Fintel reports that on September 19, 2025, JP Morgan downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Neutral to Underweight. Analyst Price Forecast Suggests 110.57% Upside As of ...
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the ...
As of September 11, 2025, Replimune Group, Inc. had a $469.1 million market capitalization, putting it in the 39th percentile of companies in the Biotechnology industry. Replimune Group, Inc. does not ...
The breach hit core JavaScript libraries such as chalk and strip-ansi, downloaded billions of times each week, raising alarms over the security of open-source software. Hackers have compromised widely ...
A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...
Shares of Replimune (NASDAQ:REPL) plunged ~38% in the premarket on Monday after Stat News reported that the FDA’s top regulator of cancer drugs intervened during the review of the company’s lead asset ...
ಕೆಲವು ಫಲಿತಾಂಶಗಳನ್ನು ಮರೆಮಾಡಲಾಗಿದೆ ಏಕೆಂದರೆ ನೀವು ಅವುಗಳನ್ನು ಪ್ರವೇಶಿಸಲು ಸಾಧ್ಯವಾಗದಿರಬಹುದು.
ಪ್ರವೇಶಿಸಲಾಗದ ಫಲಿತಾಂಶಗಳನ್ನು ತೋರಿಸಿ
ಪ್ರತಿಕ್ರಿಯೆ